What You Need to Know About Dianthus Therapeutics, Inc.'s Q3 Earnings
Dianthus Therapeutics, Inc.'s fiscal Q3 earnings report was released on Tuesday, August 04. Let's dive in to see if (DNTH) missed or beat analyst's expectations.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Commentary & Analysis
Why Dianthus Therapeutics, Inc.’s (DNTH) Stock Is Down 5.70%
As of Friday, July 31, Dianthus Therapeutics, Inc.’s DNTH share price has dipped by 5.70%, which has investors questioning if this is right time to buy.Michael Rose
Why Dianthus Therapeutics, Inc.’s (DNTH) Stock Is Up 6.27%
As of Thursday, July 30, Dianthus Therapeutics, Inc.’s DNTH share price has surged by 6.27%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Dianthus Therapeutics, Inc.’s (DNTH) Stock Is Up 5.63%
As of Friday, July 17, Dianthus Therapeutics, Inc.’s DNTH share price has surged by 5.63%, which has investors questioning if this is right time to sell.Michael Rose
Why Dianthus Therapeutics, Inc.’s (DNTH) Stock Is Down 6.40%
As of Wednesday, July 01, Dianthus Therapeutics, Inc.’s DNTH share price has dipped by 6.40%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | DNTH | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6,131.0 | $286.3 | 70% |
|
| Shares Out (Mil) | 56.0 | 54.2 | 50% |
|
| Institutional Ownership | 99.9% | 92.8% | 96% |
|
| Float (Mil) | 55.9 | 39.7 | 49% |
|
| Beta | 0.08 | 0.94 | 8% |
|
| Avg Daily Volume (000s) | 675 | 534 | 63% |
|
| Price Change (52-week) |
382.9% | 58.7% | 99% |
|
| Growth | DNTH | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 9 | |
| Current EPS | ($1.020) | ($3.920) | ($4.743) | |
| Month Ago EPS | ($1.023) | ($3.927) | ($4.651) | |
| # Rev Up | 2 | 0 | 1 | |
| # Rev Down | 1 | 2 | 0 | |
| Three Months Ago EPS | ($1.023) | ($3.899) | ($4.628) | |
| Year/Year Chg | 13.8% | (6.8%) | 35.7% | |
| Financials | DNTH | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2 | $37 | 3% |
|
| Net Income (TTM) (Mil) | ($192) | ($43) | 7% |
|
| EPS (TTM) | ($4.113) | ($1.400) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($155) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $97 | $2 | 77% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 16% |
|
| Enterprise Value (Q1) (Mil) | $5,104 | $160 | 63% |
|
| Valuation | DNTH | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.12 | 2.77 | 78% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | DNTH | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 64.2% | 96% |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (25.0%) | (47.3%) | 18% |
|
| ROE | (26.1%) | (55.0%) | 21% |
|
| Liabilities to Assets | 3.4% | 29.6% | 1% |
|
| F-Score | 4 | 2 | 34% |
|
Dianthus Therapeutics, Inc. did not pass any screens on 8/20/2026.
